The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Certolizumab safety and efficacy in clinical practice
|
A retrospective, multicenter, observational study of certolizumab pegol treatment in patients with plaque psoriasis has been published in the International Journal of Dermatology by Sahuquillo-Torralba et al.1 A total of 67 patients were evaluated in the study and were observed from the first dose of certolizumab until the date of the first missed dose.1 |
| Key learnings: |
|
Absolute PASI <3 was achieved in 69%, 86%, and 92% of patients receiving certolizumab at Weeks 12, 24, and 52, respectively, with a drug survival rate of 85% in the first year. |
|
21% of patients discontinued certolizumab, the majority due to lack/loss of effectiveness. |
|
In 14 patients who initiated treatment during pregnancy and/or lactation, there were no recorded adverse events at the time of delivery or in the neonatal period, supporting guidelines that recommend the use of certolizumab as a first-line choice of biologic for patients planning pregnancy or breastfeeding. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content